Glaukos (GKOS) AI Stock Analysis

• Market Cap: $4.70B
• Dividend Yield: N/A
• Average Volume (3M): 1.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: 30.38%
• EPS Growth: 47.64%
• Country: US
• Employees: 995
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.16
• Shares Outstanding: 57,434,740
• 10 Day Avg. Volume: 1,768,744
• 30 Day Avg. Volume: 1,285,381
• PEG Ratio: 150.23
• Price to Book (P/B): 10.31
• Price to Sales (P/S): 20.63
• P/FCF Ratio: -116.98
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 9.60
• Enterprise Value/Gross Profit: 12.49
• Enterprise Value/Ebitda: -116.09
• 1Y Price Target: $115.89
• Price Target Upside: 38.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -0.82
• Revenue Forecast (FY): $493.74M

• Rating: 52 Neutral
• Price Target: $89.00 ▲(6.13% Upside)

Glaukos's overall score is driven by strong sales growth and positive future guidance, as highlighted in the earnings call. However, significant challenges in profitability, cash flow management, and valuation metrics weigh heavily on the score. Technical indicators suggest bearish momentum, further impacting the stock's attractiveness.

Positive Factors

Revenue Growth

Exceeding revenue expectations indicates strong market demand and effective execution of strategic plans, supporting long-term growth.

Product Approval

FDA approval of Epioxa enhances product portfolio, offering a competitive edge and potential for increased market share in ophthalmic treatments.

Strategic Expansion

The new facility supports long-term growth and innovation, strengthening U.S. operations and enhancing capacity for future product development.

Negative Factors

Profitability Challenges

Ongoing profitability issues may hinder financial stability and limit reinvestment opportunities, affecting long-term business sustainability.

Cash Flow Issues

Negative cash flows indicate potential liquidity constraints, impacting the company's ability to fund operations and strategic initiatives.

Market Access Challenges

Difficulties in market access and reimbursement could limit the adoption of new products, affecting revenue growth and market penetration.

Glaukos Business Overview & Revenue Model

Company Description

Glaukos Corporation is a medical technology company focused on the development and commercialization of innovative surgical devices and therapies for the treatment of glaucoma and other diseases of the eye. Founded in 1998 and headquartered in San Clemente, California, Glaukos operates primarily in the ophthalmic sector, offering products such as the iStent and iStent inject, which are designed to reduce intraocular pressure in patients with glaucoma. The company is dedicated to enhancing patient outcomes through its minimally invasive surgical approaches, which aim to provide safer and more effective treatment options for eye care professionals and their patients.

How the Company Makes Money

Glaukos generates revenue primarily through the sale of its surgical devices and related products for the treatment of glaucoma. The company's key revenue streams include the direct sales of its iStent and iStent inject devices, as well as revenue from related consumables and accessories. Glaukos also benefits from strategic partnerships with ophthalmology clinics and hospitals, which help to expand its market reach and distribution capabilities. Additionally, the company may explore partnerships with other healthcare organizations for product development, clinical studies, and co-marketing agreements, contributing to its overall revenue growth. As the prevalence of glaucoma and the demand for innovative treatment options increase, Glaukos is positioned to capitalize on these trends within the ophthalmic market.

Glaukos Financial Statement Overview

Summary

Glaukos shows potential with revenue growth and a strong gross profit margin. However, profitability issues and negative cash flow highlight significant operational inefficiencies and cash constraints.

Income Statement

Glaukos shows a positive revenue growth trend with a TTM growth rate of 8.52%, indicating potential market expansion. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains strong at 76.87%, but the persistent negative net income highlights challenges in cost management and operational efficiency.

Balance Sheet

The balance sheet reflects a stable financial structure with a low debt-to-equity ratio of 0.14, suggesting manageable leverage. However, the negative return on equity indicates inefficiencies in generating profits from shareholders' investments. The equity ratio of 76.98% shows a strong equity base, providing a cushion against financial volatility.

Cash Flow

Cash flow analysis reveals a challenging scenario with negative operating cash flow, indicating operational cash constraints. Despite a positive free cash flow growth rate, the company struggles to convert net income into cash, as shown by the negative operating cash flow to net income ratio. The free cash flow to net income ratio above 1 suggests reliance on non-operational cash inflows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	469.82M	383.48M	314.71M	282.86M	294.01M	224.96M
Gross Profit	361.14M	289.45M	239.14M	213.88M	227.38M	133.24M
EBITDA	-38.86M	-95.64M	-82.12M	-48.76M	-1.47M	-83.59M
Net Income	-87.61M	-146.37M	-134.66M	-99.19M	-49.59M	-120.35M
Balance Sheet
Total Assets	999.38M	974.76M	940.41M	1.00B	1.05B	1.01B
Cash, Cash Equivalents and Short-Term Investments	273.71M	318.92M	295.43M	352.69M	414.05M	404.37M
Total Debt	104.31M	105.87M	383.74M	382.48M	382.38M	270.81M
Total Liabilities	229.84M	207.82M	478.65M	472.38M	462.55M	338.05M
Stockholders Equity	769.54M	766.93M	461.77M	530.00M	587.15M	667.45M
Cash Flow
Free Cash Flow	-27.61M	-67.62M	-78.01M	-63.35M	-23.08M	-29.92M
Operating Cash Flow	-21.13M	-61.32M	-57.76M	-33.08M	24.71M	-22.99M
Investing Cash Flow	-49.94M	47.83M	14.10M	44.78M	-58.23M	-205.06M
Financing Cash Flow	69.57M	91.54M	15.04M	6.25M	39.26M	262.54M

Glaukos Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 83.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GKOS, the sentiment is Neutral. The current price of 83.86 is above the 20-day moving average (MA) of 81.91, below the 50-day MA of 84.41, and below the 200-day MA of 99.24, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 51.41 is Neutral, neither overbought nor oversold. The STOCH value of 34.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GKOS.

Glaukos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UFPT	76 Outperform	$1.72B	26.20	18.31%	―	29.47%	23.24%
ITGR	63 Neutral	$2.39B	27.90	5.18%	―	7.81%	-26.32%
TNDM	57 Neutral	$900.70M	―	-111.91%	―	25.84%	-47.67%
IRTC	56 Neutral	$5.82B	―	-53.15%	―	25.45%	66.62%
GKOS	52 Neutral	$4.70B	―	-12.19%	―	30.38%	47.64%
LIVN	52 Neutral	$2.77B	―	-17.63%	―	8.97%	-1024.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Glaukos Corporate Events

Glaukos Corp. Reports Record Sales and FDA Approval

Glaukos Corp. recently held its earnings call, revealing a strong financial performance marked by record sales and significant product approvals. The sentiment was generally positive, with the FDA approval of Epioxa being a notable highlight. However, challenges remain, particularly in transitioning the Corneal Health franchise and establishing market access for new products.

Glaukos Corp. Reports Record Q3 Sales Growth

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that specializes in developing innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company is known for pioneering Micro-Invasive Glaucoma Surgery (MIGS) and continues to advance its portfolio with novel, dropless platform technologies.

Glaukos Reports Record Q3 2025 Sales Growth

In its third quarter of 2025, Glaukos reported record net sales of $133.5 million, marking a 38% increase year-over-year. The company raised its 2025 net sales guidance and introduced preliminary 2026 guidance, reflecting strong business momentum and strategic execution. Despite a net loss, the company showed improved financial performance compared to the previous year, with increased sales, gross margins, and reduced operating losses.

The most recent analyst rating on (GKOS) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.

Glaukos Corp. Advances NEXAGON® Study for Eye Condition Treatment

Glaukos Corp. is conducting a study titled ‘A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With Persistent Corneal Epithelial Defects (NEXPEDE-1)’. The study aims to assess the safety and effectiveness of NEXAGON® in treating persistent corneal epithelial defects (PCED), a condition that can lead to significant vision problems.

Glaukos Corp. Advances in Glaucoma Treatment with New Clinical Trial

Glaukos Corp. is currently recruiting participants for a Phase 2/Phase 3 clinical trial titled Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant. The study aims to assess the safety and effectiveness of the second-generation Travoprost intracameral implant in treating glaucoma, a significant eye condition that can lead to vision loss.

Glaukos Corp.’s iDose TR Study: A Potential Game-Changer in Ophthalmic Treatment

Glaukos Corp. is conducting a clinical study titled ‘Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone.’ This study aims to assess the safety and effectiveness of the iDose TR, a travoprost intracameral implant, when used alongside cataract surgery. The trial’s significance lies in its potential to offer a new treatment option for patients with open-angle glaucoma and ocular hypertension undergoing cataract surgery.

Glaukos Highlights Innovation in Recent Investor Presentation

Glaukos Corporation’s recent investor presentation highlights its strategic focus on innovation and commercial excellence, aiming to improve standards of care in ophthalmology. The company is advancing its iDose TR therapy, a groundbreaking sustained-release drug delivery system for glaucoma, which is expected to enhance patient compliance and outcomes by reducing reliance on traditional topical medications.

The most recent analyst rating on (GKOS) stock is a Buy with a $139.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.

Glaukos Corp. Reports Record Growth Amid Challenges

Glaukos Corp. recently held its earnings call, revealing a generally positive sentiment driven by strong financial performance and strategic advancements. The company reported record net sales and significant growth in key segments, such as the U.S. glaucoma franchise and international markets. Despite these achievements, challenges persist, including the impact of MAC LCDs on the MIGS market and potential disruptions from proposed CMS reimbursement changes. Nevertheless, the company’s positive achievements and strategic advancements appear to outweigh these challenges.

Glaukos Corporation Reports Strong Q2 2025 Growth

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that specializes in developing innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company is known for pioneering Micro-Invasive Glaucoma Surgery (MIGS) and continues to expand its portfolio with novel, dropless platform technologies.